Controversial Alzheimer’s Drug Approval Sparks Surprising Impact “Alzheimer’s is the most important medical condition society faces and we need an army of citizen volunteers to participate in drug trials,” said UCI MIND’s Joshua Grill, with study leader Marina Ritchie. Click to read the article
Read More
Alzheimer’s drug that slows cognitive decline gets FDA approval UCI MIND Director, Dr, Joshua Grill is quoted in the Washington Post about the meaningfulness of lecanemab's clinical benefit. Further discussion on this topic is accessible on UCI MIND blog post. Click to read the article Click to read the blog post
Read More
Meet Orange County’s 125 most influential people for 2023 Dr. Joshua Grill, Director of UCI MIND is named one of Orange County’s 125 most influential people for 2023 by the Orange County Register! Click to read the article
Read More
Why the new Alzheimer’s drug is eliciting both optimism and caution UCI MIND Director, Dr. Joshua Grill is quoted in a National Geographic article about lecanemab Click to read the article
Read More
Want to make an IMPACT in Alzheimer’s clinical trials? Apply for IMPACT-AD A training course, directed by UCI MIND Director, Dr. Joshua Grill and Director of Biostatistics at USC Alzheimer's Therapeutic Research Institute. Click to learn more about IMPACT-AD
Read More